Home / Blog / Tag / Nasopharyngeal carcinoma

Nasopharyngeal Carcinoma

Search by Categories

Trending

View All

loqtorzi-for-nasopharyngeal-carcinoma-treatment
Coherus and Junshi’s Loqtorzi: First-ever Chinese PD-1 Inhibitor and Nasopharyngeal Carcinoma Treatment

On 27 October 2023, Coherus BioSciences and Shanghai Junshi Biosciences received FDA approval for Loqtorzi (toripalimab), marking a significant milestone as the first-ever sanctioned treatment for nasopharyngeal carcinoma. The medication has gained approval for use alongside cisplatin and gemcitabine as an initial ...

Find More
Pharma News for GSK, Roche, Eli Lilly, Coherus
Phase III RUBY Trial of Jemperli Plus Chemotherapy Updates; FDA Approves Roche’s Vabysmo for RVO; FDA Grants Priority Review to Tovorafenib Low-Grade Glioma; FDA Approves Lilly’s Omvoh; FDA Approves Toripalimab for Nasopharyngeal Carcinoma; FDA Fast Track Designation to ONCT-534 R/R mCRPC

FDA Granted Fast Track Designation to Oncternal Therapeutics’s ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer On Oct. 26, 2023, Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting andr...

Find More